Localized prostate cancer

At a glance

  • Localized prostate cancer often grows very slowly.
  • The treatments are generally effective.
  • The risk of developing prostate cancer increases with age.
  • Prostate cancer screening includes palpation (touching) and a PSA test.
  • The treatment options for cancer that is growing slowly include active surveillance, radiotherapy and surgery.

Introduction

Photo of two men talking at the breakfast table

A of prostate cancer usually comes as a shock to men and those close to them. But as worrying as the is, the good news is that it is one of the types of cancer with the best chances of recovery. This is because it often grows very slowly and the treatments are generally effective.

Localized prostate cancer refers to cancer that only affects the prostate and hasn't spread to the lymph nodes or formed tumors elsewhere in the body (metastases).

Symptoms

Localized prostate cancer doesn't cause any symptoms. It normally first becomes noticeable when it reaches a more advanced stage. Then it can lead to symptoms such as an increased urge to urinate (pee) or a weaker flow of urine. In most cases, though, problems urinating aren’t caused by cancer, but by a benign enlarged prostate. This is very common in men over the age of 50. In rare cases, blood in urine or in semen can also be a sign of prostate cancer.

Very advanced prostate cancer may also spread to other parts of the body (like the bones) through the lymphatic system or the blood vessels. This can lead to symptoms such as bone pain.

Causes and risk factors

The exact causes of prostate cancer aren’t known. Certain factors can increase the risk of prostate cancer somewhat. The main ones include:

  • Age: The risk of prostate cancer increases with age. This is the biggest risk factor.
  • Close relatives: Men who have a father or brother who developed prostate cancer are at a somewhat higher risk themselves. If several close relatives have (had) prostate cancer, your risk is even higher.
  • Ethnicity : Men with dark skin are somewhat more likely to develop prostate cancer.
  • Vitamin E: Dietary supplements that have a lot of vitamin E in them have been proven to increase the risk of prostate cancer if taken over many years.

Certain types of food, such as red meat or tomatoes, are often associated with cancer. No high-quality studies have shown that men can influence their risk of getting prostate cancer or affect the course of the disease by following a specific diet.

Prevalence

The risk of prostate cancer increases with age. It is very rare in men younger than 50.

The following tables show how likely it is that a man of a certain age will be diagnosed with prostate cancer within the next ten years and how likely it is that he will die of it. These numbers are averages: A man’s individual risk will also depend on whether he has risk factors and – if so – which risk factors.

Table: Risk of being diagnosed with prostate cancer in the next ten years:
Current age Number of men who will be diagnosed with prostate cancer in the next ten years
45 4 out of 1,000
55 21 out of 1,000
65 51 out of 1,000
75 52 out of 1,000
Source: RKI 2021
Table: Risk of dying of prostate cancer in the next ten years:
Current age Number of men who will die of prostate cancer in the next ten years
45 Fewer than 1 out of 1,000
55 2 out of 1,000
65 7 out of 1,000
75 20 out of 1,000
Source: RKI 2021

Outlook

Whether and how prostate cancer continues to grow will vary from person to person. It is hard to accurately predict how prostate cancer will continue to develop in a specific man. The depends on things like the stage of the tumor and how aggressive it is. The following table shows how tumor stage and aggressiveness influence how likely it is that someone will die of prostate cancer.

Table: Effect of tumor stage and aggressiveness on likelihood of death
Type of cancer Number of men who will die of prostate cancer in the next five years
All men who have prostate cancer (localized and advanced) 10%
Men who have localized prostate cancer 3%
Men who have localized prostate cancer with low aggressiveness (low-risk prostate cancer) Less than 1%
Source: RKI 2021, Hamdy 2016

Tissue samples (biopsies) and other examinations can be used to find out whether the cancer tends to grow quickly or only very slowly. The probability that the cancer will grow is called its risk of progression.

Diagnosis

If it’s thought that a man might have prostate cancer, the doctor will first ask about his symptoms to get a rough idea of the problem and figure out what might be causing it (anamnesis). After that, one or more of the following examinations may be done:

  • Palpation (feeling): Here the doctor gently inserts a finger into the anus to feel the size, hardness and surface of the prostate (digital rectal exam, or DRE).
  • PSA test: The PSA test is a blood test that looks for a certain protein known as “prostate-specific antigen.” This protein is produced inside the prostate. Small amounts of it enter the bloodstream. Having high levels of PSA might – but doesn’t necessarily – mean that someone has prostate cancer. Other things can lead to an increase in PSA levels too.
  • Transrectal ultrasound (TRUS): Ultrasound is used to check the size and shape of the prostate gland. This involves gently inserting an ultrasound device about as wide as a finger into the (the end part of the bowel).
  • Tissue sample (biopsy): The only way to find out whether there actually is cancerous tissue in the prostate is by taking a tissue sample. Ten to twelve tissue samples are usually taken to be examined under a microscope. The most commonly used approach is called fine needle aspiration. This also involves inserting an ultrasound device into the . The device has a fine hollow needle that can puncture the prostate through the wall of the in order to take a sample of the prostate tissue. This procedure is done using a local anesthetic, or – in some rare cases – a brief general anesthetic.
  • Magnetic resonance imaging (MRI): Sometimes MRI is used in addition to taking tissue samples.

Doctors can use the results of these examinations to ma ke an educated guess about whether the cancer will grow and how fast (risk of progression).

Screening

Two of the methods used for diagnosing prostate cancer can also be used to screen for it:

  • In Germany, statutory health insurers cover the palpation of the prostate. But it doesn’t have any proven benefits. There is no proof that men are less likely to die of prostate cancer if they regularly have the palpation examination.
  • The benefits of PSA tests in prostate cancer have been investigated in large studies. The results show that, together with the advantages, there are also some serious disadvantages such as overdiagnosis. Before deciding whether to have a PSA test, it is worth carefully considering the pros and cons.

Transrectal ultrasound isn’t suitable for the detection of prostate cancer. So medical societies advise against using this examination for purposes.

Treatment

The possible treatment options for prostate cancer will depend on various factors. They include the following:

  • How much the cancer has spread (tumor stage)
  • The likely course of the disease (risk of progression)
  • Individual factors such as general health, and how important the pros and cons are to you

Depending on the situation, you can choose one of the following options:

  • Active surveillance: The prostate is checked at regular intervals. The cancer is treated only if the tumor starts growing. This strategy is an option for what is known as "low-risk" prostate cancer. It is based on the fact that low-risk prostate cancer usually grows very slowly or doesn't grow at all. This type of cancer often doesn't progress even years after it was diagnosed. The advantage: Many men can avoid the side effects of treatment. The disadvantage: If the cancer does progress, that is sometimes discovered too late. Many men find the checks to be distressing as well.
  • External radiotherapy: The cancer is exposed to radiation from outside of the body (through the skin) in order to destroy the cancer cells. The most common side effects include erection problems and bowel trouble such as diarrhea, unintentional bowel movements and blood in the stool (poo).
  • Internal radiotherapy (brachytherapy): The cancer is exposed to radiation from slightly radioactive "seeds" that are implanted inside the body. The side effects of brachytherapy are similar to those of external radiotherapy. Bowel problems are a little less common. There may also be problems with urination (peeing) in the first 1 to 2 years.
  • Removal of the prostate gland (prostatectomy): The prostate and cancer are surgically removed. Common side effects include urinary , erection problems and impotence.

If the prostate cancer has reached a more advanced stage, there are several kinds of hormonal treatments and chemotherapies that aim to slow its growth.

The strategy that you choose will mainly depend on his personal preferences and values. Some will feel it is more important to avoid side effects like impotence or as much as possible. Others will want to be as sure as possible that the cancer has been removed, so they are willing to accept the risks associated with treatment.

In older men who may have other medical conditions as well, the risks and stress associated with surgery or radiotherapy could outweigh the possible benefits of this treatment. Then "watchful waiting" is an option. In this approach, only the possible symptoms are treated, rather than the cancer itself ("palliative" treatment). Unlike "active surveillance," this allows you to avoid the distressing check-up examinations.

Further information

You will find more information about prostate cancer and the various treatment options (in German) on the website of the German Cancer Information Service (Krebsinformationsdienst ) or in the patient information accompanying the German clinical practice guidelines.

You can also read about how to find the right doctor, how to prepare for the appointment and what to remember.

Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Deutsche Krebsgesellschaft (DKG), Deutschen Krebshilfe (DKH). Prostatakarzinom (S3-Leitlinie). AWMF-Registernr.: 043-022OL (Leitlinienprogramm Onkologie). 2021.

Drost FH, Osses DF, Nieboer D et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 2019; (4): CD012663.

Hamdy FC, Donovan JL, Lane JA et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375(15): 1415-1424.

Klein EA, Thompson IM, Jr., Tangen CM et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306(14): 1549-1556.

Robert Koch-Institut (RKI), Gesellschaft der epidemiologischen Krebsregister in Deutschland (GEKID). Krebs in Deutschland für 2017/2018. Berlin: RKI; 2021.

Vernooij RW, Lancee M, Cleves A et al. Radical prostatectomy versus deferred treatment for localised prostate cancer. Cochrane Database Syst Rev 2020; 6: CD006590.

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas - either via our form or by gi-kontakt@iqwig.de. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Über diese Seite

Updated on September 16, 2022

Next planned update: 2025

Publisher:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.